Recent Updates
Recently added Catalysts

PF-07941944

Phase 1

Healthy Participants | Small molecule | Other |Pfizer, Inc.|Last Updated: Jul 17, 2025

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedCONTROLLED
Total Trials1
Total Enrollment25

FDA Designations

No designations recorded

Clinical trial landscape

PF-07941944 · 1 trial · 1 indication

Phase 1 1
NCT06920498A Study to Learn How Different Amounts of the Study Medicine Called PF-07941944 Are Tolerated in the Body of Healthy Adults.Healthy Participants
COMPLETED25 Analytics
PHASE1COMPLETED
A Study to Learn How Different Amounts of the Study Medicine Called PF-07941944 Are Tolerated in the Body of Healthy Adults.
Healthy Participants
NCT0692049825
Unlock trial analytics

Study Endpoints

Primary Endpoints

Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs)
Baseline through end of study, approximately 16 weeks

Part 1 and Part 2

Number of Participants With Clinically Significant Change From Baseline in Laboratory Abnormalities
Baseline through end of study, approximately 16 weeks

Part 1 and Part 2

Number of Participants With Clinically Significant Change From Baseline in Vital Signs
Baseline through end of study, approximately 16 weeks

Part 1 and Part 2

Number of Participants With Change From Baseline in Electrocardiogram (ECG) Findings
Baseline through end of study, approximately 16 weeks

Part 1 and Part 2

Maximum Observed Plasma Concentration (Cmax)
Baseline through end of study, approximately 16 weeks

Part 3

Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf)
Baseline through end of study, approximately 16 weeks

Part 3 - if data permit

Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)
Baseline through end of study, approximately 16 weeks

Part 3 - If AUCinf not collected

Secondary Endpoints

Cmax
Baseline through end of study, approximately 16 weeks
Time to Reach Maximum Observed Plasma Concentration (Tmax)
Baseline through end of study, approximately 16 weeks
AUClast
Baseline through end of study, approximately 16 weeks
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeBASIC_SCIENCE

Treatment Arms

ArmTypeDescription
Part 1EXPERIMENTALSingle ascending dose of PF-07941944 or placebo in healthy adult participants
Part 2EXPERIMENTALMultiple doses of PF-07941944 or placebo in healthy adult participants
Part 3 (Optional)EXPERIMENTALPeriod 1, single dose of Midazolam. Period 2, multiple doses of PF-07941944 + Midazolam

Interventions

NameTypeDescription
PF-07941944DRUGOral formulation
PlaceboDRUGOral formulation
MidazolamDRUGOral formulation
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 60 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Participants who are overtly healthy as determined by medical evaluation * Body mass index (BMI) of 17.5 to 30.5 kg/m2 * For inclusion of Japanese participants: participants who have 4 Japanese biologic grandparents who were born in Japan. Exclusion Criteria: * Evidence or h...

Countries:Belgium
Unlock Eligibility Criteria

Frequently asked questions about PF-07941944

What is PF-07941944 used for?

PF-07941944 is an investigational small molecule being studied in healthy participants. It is being evaluated to learn how different amounts of the study medicine are tolerated in the body of healthy adults. The drug is currently in Phase 1 clinical development and is not approved for any medical use.

Who makes PF-07941944?

PF-07941944 is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker symbol PFE. The company is conducting clinical research on this investigational small molecule in healthy adult participants.

What phase is PF-07941944 in?

PF-07941944 is in Phase 1 clinical development. A Phase 1 study has been completed, which involved 25 healthy adult participants in Belgium. The drug remains investigational and has not received regulatory approval for any indication.

What clinical trials is PF-07941944 in?

PF-07941944 has one completed clinical trial registered under NCT06920498. This Phase 1 study, titled 'A Study to Learn How Different Amounts of the Study Medicine Called PF-07941944 Are Tolerated in the Body of Healthy Adults,' enrolled 25 participants in Belgium. The trial was controlled but not double-blinded.

Is PF-07941944 FDA approved?

PF-07941944 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The completed Phase 1 trial assessed tolerability in healthy adults, but the drug has not yet demonstrated efficacy or received marketing authorization from regulatory authorities.